Clinical Trial Update: Phase 3 Study of ANP Therapy vs. TMZ for Optic Pathway Glioma [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial comparing ANP Therapy with temozolomide for optic pathway glioma has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Optic Nerve Glioma
• Optic Pathway Glioma

Drugs mentioned

• ANP Therapy (antineoplaston)
• Temozolomide (Temozolomide)

Snippet

Sponsor: Burzynski Research Institute | Conditions: Optic Nerve Glioma | Phase 3 | Status: WITHDRAWN